fbpx

News

The combination of two drugs showed encouraging results for patients suffering from advanced peritoneal mesothelioma.

The use of a checkpoint inhibitor along with a drug to slow the growth of new blood vessels may delay the progression of peritoneal mesothelioma as well as increase the life expectancy of patients diagnosed with the deadly disease caused by asbestos exposure.

A study by the University of Texas MD Anderson Cancer Center found that combining – atezolizumab (Tecentriq) plus bevacizumab (Avastin) – was safe and effective for peritoneal mesothelioma patients who were either intolerant to platinum-pemetrexed chemotherapy or saw the disease progress during prior treatment. The median time to next treatment increased from 8.3 months under platinum-pemetrexed chemotherapy to 17.6 months with atezolizumab/bevacizumab. One year after treatment, 61 percent of the peritoneal mesothelioma patients were progression free and 85 percent were still alive.

Malignant peritoneal is a rare and aggressive disease that is caused by on-the-job asbestos exposure, bystander or take-home exposure or the use of talcum powder. Because it is often not diagnosed until later stages, treating peritoneal mesothelioma is difficult. There are limited treatment options. Most often treatment includes a surgery to remove tumors along with chemotherapy to attempt to slow any progression. This recent study, which will need to be validated with larger clinical trials, suggests that more advanced treatments are on the horizon. That new hope presents a ray of light for peritoneal mesothelioma patients.

“Atezolizumab/bevacizumab was well tolerated and led to robust and durable responses in patients with malignant peritoneal mesothelioma who had progressed on, or were intolerant to, prior platinum-pemetrexed chemotherapy with meaningful prolongation of survival,” wrote the lead study author Kanwal P.S. Raghav, MBBS, MD, of The University of Texas MD Anderson Cancer Center. “This study establishes a promising treatment option for our patients who suffer from this morbid cancer and represents an unprecedented effort to bridge the gap of dedicated research in this … disease.”

The study was published on July 14, 2021 in the journal Cancer Discovery.

Peritoneal mesothelioma patients may wish to ask their oncologist about this new line of research and whether it is appropriate for their course of treatment.

RPWB has a 40-year history of helping people diagnosed with mesothelioma get compensation from asbestos manufacturers. We have recovered billions of dollars for our clients in their times of need. If you or a loved one is impacted by this disease, please give us a call to discuss your legal options.

How can we help? Fill out the form for a free case review.

    Contact Us

    Recent Posts

    Categories

    Related Posts